BioWorld MedTech

Sep. 5, 2018

Nexstim scraps FDA approval plans for TMS system in rehabilitation following stroke

LONDON – Nexstim plc has dropped plans to apply for FDA approval of its transcranial magnetic stimulation (TMS) system in rehabilitation following stroke, after a second U.S. phase III trial failed to reach statistical significance. Read More

Attune Medical scoops up more than $15M in oversubscribed series C

Belgian startup Miracor bumps series D up to €30M to back novel treatment after AMI

Study says CJR program cut spending without affecting outcomes

Astraea's bifunctional drug fights pain and addiction

Financings

Daily M&A

Appointments and advancements

Product briefs

Other news to note

BioWorld MedTech's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...